Dosage of enalapril for congestive heart failure in USA


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Dosage of enalapril for congestive heart failure in USA

  1. 1. Clinical Trial Commentary <ul><li>Dr Eric Topol </li></ul><ul><ul><li>Provost and Chief Academic Officer </li></ul></ul><ul><ul><li>Chairman and Professor, Department of Cardiology </li></ul></ul><ul><ul><li>Cleveland Clinic </li></ul></ul><ul><li>Dr Robert Califf </li></ul><ul><ul><li>Professor of Cardiology </li></ul></ul><ul><ul><li>Associate Vice Chancellor for </li></ul></ul><ul><ul><li>Clinical Research at Duke University </li></ul></ul>SoS
  2. 2. Study design <ul><li>International study: </li></ul><ul><li>11 European countries and Canada </li></ul><ul><li>Trial design: </li></ul><ul><li>Comparing CABG and stent-assisted angioplasty in patients with multivessel disease. </li></ul><ul><li>Primary end point: </li></ul><ul><li>need for additional revascularizations </li></ul><ul><li>Secondary end point: </li></ul><ul><li>composite of death or nonfatal Q-wave MI, and all-cause mortality. </li></ul>SoS
  3. 3. Mortality rates: SoS All deaths reported* 1.2% CABG (n=500) Mortality SoS All deaths at 1 year 4.1% 2.5% 0.8% PCI (n=488) * As of presentation at ACC 2001; p value = 0.007
  4. 4. An unexpected result <ul><li>Some explanations for the finding: </li></ul><ul><li>CABG was remarkably well done </li></ul><ul><li>8 cancer deaths in the PCI arm skewed the results </li></ul><ul><li>Repeat TVR was less surprising: </li></ul><ul><li>20.3% for PCI </li></ul><ul><li>5.8% for CABG </li></ul>SoS
  5. 5. Mortality rate: ARTS All deaths* 2.8% CABG (n=605) Mortality at 1 year SoS 2.5% PCI (n=600) *p value = n/s Serruys et al. N Engl J Med 2001; 344: 1117-24.
  6. 6. Response to the study <ul><li>SoS has an imbalance in mortality risk favoring bypass surgery. </li></ul><ul><li>The interventional cardiology community largely ignored SoS, as if they dismissed it because they didn’t like the data. </li></ul><ul><li>Topol </li></ul>SoS
  7. 7. Confusing results <ul><li>This reinforces my belief that the more complicated the anatomy, the better CABG is than PCI. </li></ul><ul><li>Nothing has convinced me that stenting will fix that for PCI. </li></ul><ul><li>Stenting does reduce the number of repeat revascularizations. </li></ul><ul><li>Califf </li></ul>SoS
  8. 8. Plumbing <ul><li>“ I really do think that ultimately for bad multi-vessel disease it boils down to a matter of plumbing -- how many open conduits do you have? And it’s going to be pretty hard to beat surgery in this regard.” </li></ul><ul><li>Dr Robert Califf </li></ul><ul><ul><li>Professor of Cardiology </li></ul></ul><ul><ul><li>Associate Vice Chancellor for </li></ul></ul><ul><ul><li>Clinical Research at Duke University </li></ul></ul>SoS
  9. 9. Quality of surgery <ul><li>The excess in cancer deaths is a fluke, but the cardiovascular deaths still show the same trend. </li></ul><ul><li>Surgical quality is critical, especially in clinical trials. </li></ul><ul><li>The quality of the surgery isn’t consistent across the globe. </li></ul><ul><li>Califf </li></ul>SoS
  10. 10. CABG mortality <ul><li>But this rate of first-operation mortality for bypass, in the peri-1%, that's not so unusual these days, is it? </li></ul><ul><li>Topol </li></ul><ul><li>For patients who qualify for PCI, it isn’t that much of a surprise. I'll bet if you look at the Cleveland Clinic, at patients like this, it's considerably less than 1%. So I don't think the trial is totally a fluke. </li></ul><ul><li>Califf </li></ul>SoS
  11. 11. Small diabetic population <ul><li>So few patients with insulin-dependent diabetes makes the results even more striking. </li></ul><ul><li>Califf </li></ul><ul><li>There wasn't much in the way of IIb/IIIa inhibitor use in the trial, which might have neutralized some of the stent liability in diabetics, but that wasn't the case. </li></ul><ul><li>Topol </li></ul>SoS
  12. 12. RITA trial <ul><li>RITA trial </li></ul><ul><li>mortality at 2.5 year follow-up: </li></ul><ul><li>3.6% for CABG </li></ul><ul><li>3.1% for PTCA </li></ul><ul><li>RITA was discounted by the interventional cardiology community because they didn't like the data. </li></ul><ul><li>SoS was rigorously done and the cancer deaths don’t explain it away. </li></ul><ul><li>Topol </li></ul>SoS
  13. 13. Pump head <ul><li>SoS included a prospective assessment on congnitive function. </li></ul><ul><li>Some have discounted surgery's success in the trial because of “pump head.” (The patients are alive but their brain isn’t working.) </li></ul><ul><li>Topol </li></ul>SoS
  14. 14. Cognitive decline with CABG Percentage of patients suffering decline in cognitive function by > 20% post-CABG compared to pre-CABG baseline At 5 years At discharge Newman et al. N Engl J Med 2001; 344: 395-402. 53% At 6 weeks 36% 24% 42% At 6 months SoS
  15. 15. Cognitive decline in SoS <ul><li>I would be surprised if cognitive decline is a factor. </li></ul><ul><li>Patients who are at highest risk for &quot;pump head&quot; tend to be the worst candidates for PCI: </li></ul><ul><li>horrific atherosclerosis </li></ul><ul><li>LV dysfunction </li></ul><ul><li>elderly </li></ul><ul><li>Califf </li></ul>SoS
  16. 16. MASS, ARTS, SoS <ul><li>Three trials have not settled the question: </li></ul><ul><li>ARTS, SoS, MASS </li></ul><ul><li>Just stenting has not achieved parity in outcomes. </li></ul><ul><li>The disparity in mortality remains troubling. </li></ul><ul><li>Topol </li></ul>SoS
  17. 17. Putting it together <ul><li>The studies need to be looked at side by side, in an overview as well as separately. </li></ul><ul><li>Unfortunately, in this field, it hasn't been done as effectively as it has been for other medical therapies (eg BARI). </li></ul><ul><li>To this day, there still is not a by-patient systematic overview of bypass surgery vs angioplasty. </li></ul><ul><li>Califf </li></ul>SoS
  18. 18. Best of both worlds. SoS <ul><li>“ It seems to me that ultimately the two procedures need to be combined. That there are probably some vessels within a patient that would do just as well with a stent, and there are others that perhaps are ideal for off-pump bypass. And that somehow combining those two, you ought to be able to get the best of both worlds.” </li></ul><ul><li>Dr Robert Califf </li></ul><ul><ul><li>Professor of Cardiology </li></ul></ul><ul><ul><li>Associate Vice Chancellor for </li></ul></ul><ul><ul><li>Clinical Research at Duke University </li></ul></ul>
  19. 19. Hybrid procedure. <ul><li>A hybrid procedure will be increasingly popular. </li></ul><ul><li>Stenting will continue to get better, with coated stents and with better adjunctive medications. </li></ul><ul><li>Off-pump surgery, and ultimately even percutaneous bypass might be possible. </li></ul><ul><li>Topol </li></ul>SoS
  20. 20. Dichotomization <ul><li>We only have three trials so far - it would be hard to say that bypass surgery is the treatment of choice for multivessel disease. </li></ul><ul><li>I don’t think the interventional cardiology community is going to succumb just yet </li></ul><ul><li>Topol </li></ul><ul><li>There is some dichotomization due to trade-unionism, which I hope we can get over. </li></ul><ul><li>Califf </li></ul>SoS
  21. 21. Surgery or stenting, who decides? <ul><li>“ In the best of all worlds it would be nice to have an independent opinion. Ideally, it would be nice if you had this really proficient angiographer who didn't necessarily do interventions, or would be able to review a cath without a bias, to be the honest broker to make decisions. But we don't have that.” </li></ul><ul><li>Dr Eric Topol </li></ul><ul><ul><li>Provost and Chief Academic Officer </li></ul></ul><ul><ul><li>Chairman and Professor, Department of Cardiology </li></ul></ul><ul><ul><li>Cleveland Clinic </li></ul></ul>SoS
  22. 22. Enough for everyone <ul><li>Operator experience is a factor, some of the most experienced operators tend to be very aggressive. </li></ul><ul><li>Topol </li></ul><ul><li>With the aging population, there should be enough business for everyone. There should be a more rational system to have the right patient get the right procedure. </li></ul><ul><li>Califf </li></ul>SoS
  23. 23. SoS trial review <ul><li>Dr Robert Califf </li></ul><ul><li>One thumb up </li></ul><ul><li>&quot;We need to see the final data; particularly the quality-of-life data.&quot; </li></ul>SoS
  24. 24. SoS trial review <ul><li>Dr Eric Topol </li></ul><ul><li>Two thumbs up </li></ul><ul><li>“ Well done, well-presented, and just the kind of trial we need.” </li></ul>SoS